Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1061983 · FYE Dec 31 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $80.42Day +2.60%Mkt cap $9.8B1Y +122.3%Off 52W high −8.9%Vol (1Y) 61.1%
Daily closing price, split-adjusted to the current basis; 3y shown of 5,294 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest13.7% of sh out |
| Days to cover9.0d |
| 13F net flow (QoQ)−9.79% |
| Top-10 13F concentration54.4% |
| Next report (est.)2026-08-04 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$105.8M |
| Earnings (TTM)-$829.6M |
| Net margin−891.6% |
| Sales growth 3Y−2.4% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+26.6% |
| 1Y+122.3% |
| 3Y+141.1% |
| 5Y+171.0% |
| 10Y+599.9% |
| Since incept. (ann.)+2.1% |
Total return through 2026-07-30 · series begins 2005-07-11. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)61.1% |
| Ann. volatility (3Y)74.5% |
| Sharpe (1Y)1.61 |
| Sharpe (3Y)0.71 |
| Max drawdown (1Y)−15.0% |
| Max drawdown (3Y)−72.4% |
| Beta (3Y vs SPY)1.18 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 17.5M | $1.2B | — | −35.4% |
| BlackRock, Inc. | 16.5M | $1.1B | — | +0.9% |
| FMR LLC | 10.7M | $707M | — | −16.3% |
| WELLINGTON MANAGEMENT GROUP LLP | 8.0M | $528M | — | +0.9% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 5.8M | $385M | — | new |
| STATE STREET CORP | 5.7M | $379M | — | −1.4% |
| VANGUARD CAPITAL MANAGEMENT LLC | 5.5M | $362M | — | new |
| Avoro Capital Advisors LLC | 3.3M | $220M | — | new |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total. % of shares outstanding suppressed: the summed institutional 13F holdings (146,192,836) exceed the cover-page shares-outstanding count for this quarter (123,162,807, as of 2026-02-23) by more than securities-lending double counting can explain (FINRA short interest 15,896,196 shares at 2026-04-30), so the share count is stale or wrong (common for annual 20-F foreign private issuers after a share issuance) and a percentage would be fabricated. Holder share counts are shown as filed.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-05 | −$1.67 | — | $19.4M | +1125.8% |
| 2025-12-31 | 2026-02-24 | — | — | $17.8M | +4.9% |
| 2025-09-30 | 2025-11-05 | −$2.55 | — | $1.9M | +318.1% |
| 2025-06-30 | 2025-08-07 | −$1.12 | — | $66.8M | +26714.9% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-04 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
License And Milestone Revenues 90% · Collaboration Revenues 10%
product & service · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
